Repligen Seeks To Block Launch Of Bristol-Myers Drug
The lawsuit, filed by Repligen Corp., marks a change in tactic for the biotech company, which previously sued Bristol-Myers over ownership rights to a different patent for the same technology.
Repligen lost those legal bids. But now the company is trying a new approach, suing Bristol-Myers for infringement of another patent, issued in 2004 to the same...
To view the full article, register now.